Clinical Trials Logo

Embolism and Thrombosis clinical trials

View clinical trials related to Embolism and Thrombosis.

Filter by:

NCT ID: NCT00830570 Completed - Clinical trials for Venous Thromboembolism

The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

MHSMayoWarf1
Start date: July 2007
Phase: N/A
Study type: Observational

The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) testing within a primary patient care setting.

NCT ID: NCT00670540 Completed - Pulmonary Embolism Clinical Trials

Epidemiology of Thromboembolism Disease: A Cohort Study

OPTIMEV
Start date: November 2004
Phase: N/A
Study type: Observational

The purpose of this study is to determine different risk factors of thromboembolic disease. Different points will be studied 1. do different types of thromboembolic disease (distal Deep Vein Thrombosis (DVT), proximal DVT, Pulmonary Embolism (PE) and DVT, PE without DVT) have the same clinical significance (risk factors and prognosis) ? 2. Is it necessary to obtain a detailed history of thromboembolic disease ? 3. Do older patients have particular risk factors ? 4. Do preventive treatments modify the level of risk factors and the clinical signs of thromboembolic disease ? 5. Do predictive clinical scores have the same performance for both in and outpatients ? 6. Can patients with a potential high level of thromboembolic risk (surgery, pregnancy) but no clinical thromboembolic symptoms, develop a low risk ? 7. The evolution of the disease in patients with negative or positive Venous ThromboEmbolism (VTE) exploratory tests.

NCT ID: NCT00216866 Completed - Clinical trials for Embolism and Thrombosis

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

Start date: September 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to obtain an estimate of catheter survival in the setting of upper extremity deep vein thrombosis (UEDVT) in patients treated with dalteparin and warfarin. Anticoagulation with dalteparin and warfarin in patients with UEDVT secondary to central venous catheters in patients with an active malignancy is an effective therapy as quantified by the success of catheter preservation. A prolonged line salvage rate without a recurrence of UEDVT will improve the management of cancer patients who develop upper extremity deep venous thrombosis in the setting of a central venous (CV) catheter.

NCT ID: NCT00119457 Completed - Clinical trials for Venous Thromboembolism

Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.

NCT ID: NCT00059293 Completed - Clinical trials for Cerebrovascular Disorders

Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG

Start date: September 2002
Phase:
Study type: Observational

To use transcranial Doppler (TCD) ultrasound to detect stroke risk in children with sickle cell disease.

NCT ID: NCT00000592 Completed - Clinical trials for Hematologic Diseases

Stroke Prevention in Sickle Cell Anemia (STOP 1)

Start date: July 1994
Phase: Phase 3
Study type: Interventional

To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.

NCT ID: NCT00000517 Completed - Clinical trials for Cardiovascular Diseases

Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)

Start date: July 1985
Phase: Phase 3
Study type: Interventional

To determine the benefits and risks of oral anticoagulant therapy in reducing embolic stroke and systemic emboli in patients with atrial fibrillation without rheumatic heart disease.